Accessibility Menu
Osteopore logo

Osteopore(ASX) OSX

Market CapA$2.77MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-100%
5 Year-100%
1 Year-50%
1 Month-20%
A$0.00
+0.00%
+0.00Today
Osteopore last closing stock price
MetricPriceDate
Last closeAUD 0.002026-08-13
Osteopore stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-20%AUD 0.012026-08-06
1 month-20%AUD 0.012026-07-14
3 month-33.33%AUD 0.012026-05-15
Year to date-33.33%AUD 0.012025-12-31
1 year-50%AUD 0.012025-08-13
3 year-97.36%AUD 0.152023-08-14
5 year-99.51%AUD 0.812021-08-13
Since inception-99.79%AUD 1.922019-09-23

Osteopore Financials at a Glance

Market Cap

A$2.77MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$5.87M

Net Income (TTM)

-A$6.97M

EPS (TTM)

-A$0.02

P/E Ratio

-0.20

Dividend

A$0.00

Beta (Volatility)

-0.57 (Low)

Price

A$0.00

Volume

0

Open

A$0.00

Previous Close

A$0.00

Daily Range

A$0.00 - A$0.00

52-Week Range

A$0.00 - A$0.03

Estimated Earnings Date

Feb 26, 2026

OSX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Osteopore

Osteopore Limited is a pioneering company focused on engineering and manufacturing bioresorbable polymer implants for medical applications. Established in Singapore in 2003, the company specializes in creating advanced devices for neurosurgical, orthopedic, and maxillofacial procedures, utilizing innovative 3D printing technology.

Products and Services
  • Osteoplug: A resorbable implant for sealing burr holes in neurosurgery
  • Osteomesh: A resorbable implant for craniofacial surgery, addressing various fractures
  • Collaborative projects with Livingstone Health for new bone and tissue regeneration products
Growth Outlook
  • Recent quarterly revenue reached AUD 1,498,251, indicating strong market demand
  • Partnerships aim to expand product offerings in bone regeneration technology
  • Focus on international markets enhances growth potential beyond Singapore and Australia
Financial Highlights
  • Trailing twelve months (TTM) revenue of AUD 5,882,000 reflects a growing customer base
  • Gross profit margin improved to 61.94% in the latest quarter, showcasing operational efficiency
  • Cash and cash equivalents stood at AUD 626,972, providing liquidity for ongoing projects
Osteopore Limited is positioned at the forefront of medical innovation, particularly in the field of bioresorbable implants. The company's commitment to research and development, coupled with strategic partnerships, supports its mission to enhance surgical outcomes and patient recovery. With a focus on expanding its product portfolio and entering new markets, Osteopore presents a compelling opportunity for investors interested in the healthcare sector. The recent financial performance indicates a positive trajectory, with increasing revenue and improving margins, suggesting a robust foundation for future growth.
AI Generated • Aug 1, 2026

Industry

Healthcare Equipment and Supplies

CEO

Yu Jing Lim, PhD

Headquarters

Perth, WA 6000, AU

OSX Financials

Key Financial Metrics (TTM)

Gross Margin

61.94%

Operating Margin

-98.88%

Net Income Margin

-121.76%

Return on Equity

346.27%

Return on Capital

N/A

Return on Assets

-134.17%

Earnings Yield

-5.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$2.77MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

693.59M

Volume

0

Avg. Volume

3.77M

Financials (TTM)

Gross Profit

A$4.00M

Operating Income

-A$6.08M

EBITDA

-A$4.67M

Operating Cash Flow

-A$5.77M

Capital Expenditure

-A$25.39K

Free Cash Flow

-A$5.79M

Cash & ST Invst.

A$626.97K

Total Debt

A$198.80K

Osteopore Performance Analysis

Osteopore annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31AUD 1,692,38752.1%
20232023-12-31AUD 2,217,40931.0%
20242024-12-31AUD 2,762,78224.6%
20252025-12-31AUD 3,057,09810.7%
Osteopore sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3021.0%
Q42024-12-31-9.5%
Q22025-06-3016.7%
Q42025-12-31-3.9%
Osteopore annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31AUD -0.099.9%
20232023-12-31AUD -0.1451.9%
20242024-12-31AUD -0.04-68.7%
20252025-12-31AUD -0.02-53.7%
Osteopore sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3092.2%
Q42024-12-31-13.5%
Q22025-06-3044.4%
Q42025-12-31-24.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

A$1.50M

+22.8%

Gross Profit

A$700.53K

+3.1%

Gross Margin

46.76%

N/A

Market Cap

A$2.77MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$184.96K

N/A

Employees

15

N/A

Net Income

-A$2.09M

-10.6%

EBITDA

-A$1.12M

+27.2%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

A$626.97K

-43.8%

Total Debt

A$198.80K

-81.8%

Accounts Receivable

A$1.05M

+62.7%

Inventory

A$362.86K

+30.1%

Long Term Debt

A$86.99K

N/A

Short Term Debt

A$111.81K

-89.8%

Return on Assets

-1.34%

N/A

Return on Invested Capital

11.02%

N/A

Free Cash Flow

-A$1.28M

+28.6%

Operating Cash Flow

-A$1.28M

+28.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CTQ.AXCareteq Limited
A$0.01+0.00%
EXL.AXElixinol Wellness Limited
A$0.01+0.00%
BIT.AXBiotron Limited
A$0.00+0.00%
OAK.AXOakridge International Limited
A$0.08+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About OSX

What is the current price of Osteopore?

Osteopore is trading at A$0.00 per share.

What is the 52-week range for Osteopore?

Over the past 52 weeks, Osteopore has traded between A$0.00 and A$0.03.

How much debt does Osteopore have?

As of the most recent reporting period, Osteopore reported total debt of A$2.79M.

How much cash does Osteopore have on hand?

Osteopore reported A$626.97K in cash and cash equivalents in its most recent financial results.

What is Osteopore’s dividend yield?

Osteopore does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.